Search Results - "Nam, David"

Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection by Adaikkan, Chinnakkaruppan, Middleton, Steven J., Marco, Asaf, Pao, Ping-Chieh, Mathys, Hansruedi, Kim, David Nam-Woo, Gao, Fan, Young, Jennie Z., Suk, Ho-Jun, Boyden, Edward S., McHugh, Thomas J., Tsai, Li-Huei

“…Neuronal and synaptic loss is characteristic in many neurodegenerative diseases, such as frontotemporal dementia and Alzheimer’s disease. Recently, we showed…”
Get full text

Multi-sensory Gamma Stimulation Ameliorates Alzheimer’s-Associated Pathology and Improves Cognition by Martorell, Anthony J., Paulson, Abigail L., Suk, Ho-Jun, Abdurrob, Fatema, Drummond, Gabrielle T., Guan, Webster, Young, Jennie Z., Kim, David Nam-Woo, Kritskiy, Oleg, Barker, Scarlett J., Mangena, Vamsi, Prince, Stephanie M., Brown, Emery N., Chung, Kwanghun, Boyden, Edward S., Singer, Annabelle C., Tsai, Li-Huei

“…We previously reported that inducing gamma oscillations with a non-invasive light flicker (gamma entrainment using sensory stimulus or GENUS) impacted…”
Get full text

Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells by Ruhland, Megan K., Roberts, Edward W., Cai, En, Mujal, Adriana M., Marchuk, Kyle, Beppler, Casey, Nam, David, Serwas, Nina K., Binnewies, Mikhail, Krummel, Matthew F.

“…Generation of tumor-infiltrating lymphocytes begins when tumor antigens reach the lymph node (LN) to stimulate T cells, yet we know little of how tumor…”
Get full text

Short Symptom Duration Is Associated With Superior Outcomes in Patients Undergoing Primary Hip Arthroscopy: A Systematic Review by Kim, David Nam-Woo, Lee, Michael S., Mahatme, Ronak J., Gillinov, Stephen M., Islam, Wasif, Fong, Scott, Lee, Amy Y., Abu, Seyi, Pettinelli, Nicholas, Medvecky, Michael J., Jimenez, Andrew E.

“…To evaluate the effect of duration of preoperative hip pain symptoms on outcomes in patients undergoing primary hip arthroscopy for the treatment of…”
Get full text

Factors affecting outcomes of second intent healing of nasal defects after Mohs micrographic surgery by Kim, David Nam-Woo, Kibbi, Nour, Christensen, Sean R., Leffell, David J., Suozzi, Kathleen C.

“…Reconstruction of nasal defects secondary to Mohs micrographic surgery (MMS) presents particular challenges related to the complex topography, skin quality,…”
Get full text

Preresidency Publication Productivity of U.S. Neurosurgery Interns by Duy, Phan Q., Paranjpe, Manish D., Antwi, Prince, Diab, Nicholas S., Wang, Jason K., Kim, David Nam-Woo, Moushey, Alexander M., David, Wyatt B., Kapadia, Kush, Agarwal, Ank A., Huang, Jinny, Sheth, Amar H., Mekbib, Kedous, Chen, H. Alexander, Negoita, Serban, Liu, Fuchen, Takeo, Yutaka, Paranjpe, Ishan, Manna, Sayan, Mehta, Sumarth K., Gerrard, Jason L.

“…Research experience is believed to be an important component of the neurosurgery residency application process. One measure of research productivity is…”
Get full text

Mid- to Long-Term Outcomes in Patients After Hip Arthroscopy With Labral Reconstruction: A Systematic Review by Kim, David Nam-Woo, Fong, Scott, Park, Nancy, Simington, Jacquelyn, Atadja, Louise, Pettinelli, Nicholas, Lee, Michael S., Gillinov, Stephen M., Maldonado, David R., Jimenez, Andrew E.

“…Background: There is a paucity of aggregate data documenting mid- to long-term outcomes of patients after hip arthroscopy with labral reconstruction. Purpose:…”
Get full text

A Popularity Contest? Exploring Predictors of Faculty Influence in Criminology and Criminal Justice by Nam, Yongjae (David), Gormely, Alexandra, Maskály, Jon, Morgan, Skyler, Liu, Yang (Vincent), Dunn, Katherine, Bennett, Richard R., Kutnjak Ivković, Sanja

“…Our study analyzes the factors associated with the faculty influence. We explore Google Scholar citation counts of 226 faculty at the top 20 doctoral programs…”
Get full text

Patients Undergoing Primary Hip Arthroscopy Report Favorable Outcomes at Minimum 10 Year Follow-Up: A Systematic Review by Lee, Michael S., Nam-Woo Kim, David, Moran, Jay, Gillinov, Stephen M., Mahatme, Ronak J., Monahan, Peter F., Islam, Wasif, Mclaughlin, William M., Grimm, Nathan L., Jimenez, Andrew E.

“…(1) To evaluate minimum 10-year PROs (patient-reported outcomes) and survivorship after primary hip arthroscopy and (2) to identify predictors of failure for…”
Get full text

Machine Learning–Based Surveillance Strategy after Complete Ablation of Initially Recurrent Hepatocellular Carcinoma: Worth the Risk? by Nam, David, Chapiro, Julius

Get full text

Analysis of the Frequency, Characteristics, and Reasons for Termination of Spine-related Clinical Trials by Caruana, Dennis L., Nam-Woo Kim, David, Galivanche, Anoop R., David, Wyatt B., Justen, Marissa A., Moushey, Alexander M., Sheth, Amar H., Paranjpe, Manish D., Grauer, Jonathan N.

“…Cross-sectional analysis of completed and terminated spine-related clinical trials in the ClinicalTrials.gov registry. The aim was to quantify completed and…”
Get full text

Artificial intelligence in liver diseases: Improving diagnostics, prognostics and response prediction by Nam, David, Chapiro, Julius, Paradis, Valerie, Seraphin, Tobias Paul, Kather, Jakob Nikolas

“…Clinical routine in hepatology involves the diagnosis and treatment of a wide spectrum of metabolic, infectious, autoimmune and neoplastic diseases. Clinicians…”
Get full text

Abstract 3968: OT-101/Chemotherapy - A novel mechanism of action (MOA) in pancreatic cancer immunization therapy by Nam, David, Hwang, Larn, Trieu, Vuong

“…Abstract Background: OT-101 is a phosphorothioate antisense oligodeoxynucleotide targeting the human TGF-β2 mRNA. OT-101 breaks down immune tolerance and…”
Get full text

Breaking immune tolerance for the treatment of pancreatic cancer: Phase I/II clinical experience by Nam, David, Hwang, Larn, Trieu, Vuong N.

“…Abstract only 54 Background: Escalating Intratumoral heterogeneity resulting in xenogenization which is countered by overexpression of TGF-β. Here we report on…”
Get full text

Breaking immune tolerance for the treatment of glioblastoma: Phase IIb clinical trial experience by Hwang, Larn, Nam, David, Trieu, Vuong N.

“…Abstract only 71 Background: Intratumoral heterogeneity (IH) resulting in the temporal and spatial diversification of tumor subclones. IH occurs progressively…”
Get full text

Design of an Indirectly Coupled Filter Building Block for Modular Interleaved AC-DC Converters by Phukan, Ripun, Nam, David, Ohn, Sungjae, Mondal, Gopal, Nielebock, Sebastian, Dong, Dong, Burgos, Rolando

“…This article presents the analysis and realization of a modular interconnected filter building block (FBB) operating under a single and multichannel (parallel…”
Get full text

Performance Evaluation of Feature Detectors and Descriptors Beyond the Visible by Mouats, Tarek, Aouf, Nabil, Nam, David, Vidas, Stephen

“…Feature detection and description algorithms represent an important milestone in most computer vision applications. They have been examined from various…”
Get full text

Abstract 5029: OT-101/Chemotherapy- A novel mechanism of action (MOA) in glioblastoma immunization therapy by Hwang, Larn, Nam, David, Uckun, Fatih, Trieu, Vuong

“…Abstract Background: Escalating Intratumoral heterogeneity (IH) resulting in xenogenization which is countered by overexpression of TGF-β2. OT-101 is a…”
Get full text

ATIM-10. CLINICAL PREDICTORS OF RESPONSE FOR RECURRENT/REFRACTORY GLIOBLASTOMA MULTIFORME (GBM) AND ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE III) PATIENTS TREATED WITH THE ANTI-TGFß2 RNA THERAPEUTIC OT-101 by Qazi, Sanjive, Nam, David, Hwang, Larn, Trieu, Vuong, Uckun, Fatih

“…Abstract BACKGROUND OT-101 is a first-in-class αTGF-ß2 RNA therapeutic and exhibits significant single-agent activity in patients with recurrent/refractory…”
Get full text

ATIM-06. TREATMENT OF RECURRENT/REFRACTORY (R/R) ANAPLASTIC ASTROCYTOMA (AA, WHO GRADE 3) PATIENTS WITH ANTI-TGFß2 RNA THERAPEUTIC OT-101 VERSUS TEMOZOLOMIDE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL by Uckun, Fatih, Qazi, Sanjive, Nam, David, Hwang, Larn, Trieu, Vuong

“…Abstract BACKGROUND OT-101 is a first-in-class RNA therapeutic designed to disrupt the immunosuppressive action of TGFß2. During Phase 1 clinical trials,…”
Get full text